An obsession seems to linger in the minds of AI leaders: psychedelics.It wouldn’t be the first time that prominent figures have become enthusiastic about envisioning a future where the use of these substances is encouraged, or even proposed as life-saving for humanity.In the '50s, pro- LSD propaganda made its appearance even in popular magazines, with Cary Grant and other Hollywood celebrities who praised its healing, transformative properties. A sort of panacea for mental health.Today, we’re witnessing a r ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Atai Life Sciences ATAI and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).Patients were given an 8 mg dose of BPL-003 followed by a 12 mg dose two weeks later.Key FindingsFollowing the first (8 mg) dose, patients experienced a mean MADRS (Montgomery-Asberg Depression Rating Scale) reduction of ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are sustained for up to 3 monthsThe second dose of BPL-003 led to further reductions in MADRS scores from baseline, indicating that this regimen has the potential to enhance the clinical response beyond what is observed with a single administrationFindings will be us ...

AI能源需求激增 - AI是史上最耗电的技术 每个支持大型语言模型的数据中心耗电量相当于一个小型城市 [2] - AI查询 模型更新和机器人突破消耗大量能源 正在将全球电网推向崩溃边缘 [1][2] - OpenAI创始人警告AI未来取决于能源突破 Elon Musk预测明年将出现电力短缺 [2] 被忽视的能源基础设施机会 - 一家鲜为人知的公司拥有关键能源基础设施资产 将受益于AI能源需求激增 [3] - 该公司定位为AI能源繁荣的"收费亭"运营商 从每度出口电力中收取费用 [4][6] - 拥有核能基础设施资产 处于美国下一代电力战略的核心位置 [7] 多元化业务布局 - 是全球少数能执行石油 天然气 可再生燃料和工业基础设施大型EPC项目的公司之一 [7] - 在美国LNG出口领域扮演关键角色 该行业将在"美国优先"能源政策下爆发式增长 [7] - 受益于特朗普关税政策推动的制造业回流 将优先获得设施重建和改造项目 [5] 卓越的财务表现 - 公司完全无负债 与背负巨额债务的能源和公用事业公司形成鲜明对比 [8] - 持有大量现金储备 相当于其总市值的近三分之一 [8] - 按剔除现金和投资后的估值计算 交易市盈率不足7倍 [10] 战略投资布局 - 持有另一家热门AI公司的重大股权 为投资者提供多重AI增长引擎的间接曝光 [9] - 拥有实际现金流 关键基础设施和其他主要增长故事的股权 而非炒作型股票 [11] - 对冲基金开始在闭门投资峰会上推荐该股票 认为其估值极度低估 [9] 多重增长催化剂 - 受益于AI基础设施超级周期 特朗普时代关税推动的回流潮 美国LNG出口激增三大趋势 [14] - 在核能领域拥有独特布局 核能是清洁可靠电力的未来 [14] - 公司同时受益于AI 能源 关税和回流四大趋势的协同效应 [6]

5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorderNEW YORK and AMSTERDAM, Sept. 18, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that it has been awarded a multi-year, milestone-driven grant w ...

Atai Life Sciences (NasdaqGM:ATAI) FY Conference September 17, 2025 10:00 AM ET Company ParticipantsKevin Craig - Chief Medical OfficerSrinivas Rao - Co-Founder, CEO & DirectorAthena Chin - Biotechnology Equity Research AssociateConference Call ParticipantsRitu Baral - MD & Senior Biotechnology AnalystRitu BaralGood morning, everyone. Thanks for joining us today for the Atai Life Sciences fireside chat, at the TD Cowen Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Conference. I am covering analys ...